Orphazyme
We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC). In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc. Orphazyme
Basic Information
- Category: Rare Diseases
- Founded: 2009
- Headquarters: Copenhagen, Denmark
- Website: orphazyme.com
Documented Facts
- Parent company: KemPharm (No linked source recorded for this statement.)
Evidence and Sources
- Orphazyme — Official Site (official)
Citation Guidance
Explore Rare Diseases profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Orphazyme.
- Canonical profile: https://brandsource.ai/brands/orphazyme
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/orphazyme/json-ld
- Citation profile API: https://brandsource.ai/api/brands/orphazyme/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:03.995Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC). In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc. Orphazyme
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.